126:@0.085158:0.957873:0.109689:0.957873:0.109689:0.938882:0.085158:0.938882:0.007346:0.008593:0.008591
5:@0.038824:0.435294:0.060302:0.435294:0.060302:0.387816:0.038824:0.387816:0.021478
CHAPTER 5:@0.117647:0.067219:0.190589:0.067219:0.190589:0.047140:0.117647:0.047140:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.008487
Detection of somatic SVs in cfDNA from patients with ovarian and prostate cancer :@0.117647:0.122511:0.851495:0.122511:0.851495:0.099351:0.117647:0.099351:0.011231:0.009363:0.008616:0.009363:0.010905:0.008616:0.004856:0.011256:0.011679:0.003984:0.011256:0.008840:0.003984:0.010409:0.011256:0.014817:0.009463:0.008616:0.004856:0.011007:0.003984:0.010257:0.010011:0.010409:0.003984:0.004856:0.011679:0.003984:0.011007:0.008840:0.011231:0.011679:0.010309:0.003984:0.008840:0.011079:0.011256:0.014817:0.003984:0.010110:0.009463:0.008616:0.004856:0.009363:0.011679:0.008516:0.010409:0.003735:0.015987:0.004856:0.008616:0.011579:0.003984:0.011106:0.009288:0.010558:0.011231:0.004856:0.010558:0.011679:0.003733:0.010558:0.011679:0.011231:0.003984:0.010733:0.011081:0.011256:0.010309:0.007520:0.009463:0.008616:0.009363:0.003984:0.010905:0.010558:0.011679:0.011007:0.009363:0.011231:0.003984
To show the applicability of the pipeline to detect clinically relevant biomarkers, we next :@0.117647:0.168844:0.857121:0.168844:0.857121:0.148471:0.117647:0.148471:0.010866:0.011048:0.004086:0.007556:0.011299:0.010866:0.014723:0.004086:0.006617:0.011302:0.009039:0.004086:0.008811:0.011048:0.011162:0.005250:0.005547:0.009108:0.009108:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.004086:0.010843:0.006209:0.004086:0.006620:0.011302:0.009039:0.004086:0.011071:0.005273:0.011505:0.008948:0.005250:0.005615:0.011596:0.009039:0.004086:0.006209:0.011048:0.004086:0.011324:0.009128:0.006209:0.009108:0.009108:0.006437:0.004086:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009402:0.005387:0.005182:0.009724:0.004086:0.007442:0.008948:0.005182:0.009336:0.009838:0.009085:0.011391:0.006437:0.004086:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010274:0.009039:0.007622:0.007670:0.004497:0.004086:0.014518:0.009039:0.004086:0.011596:0.009108:0.010089:0.006437:0.004109
tested if we could detect the validated somatic SVs in cfDNA of patients. Ascites fluid, :@0.117647:0.189423:0.856956:0.189423:0.856956:0.169050:0.117647:0.169050:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.005570:0.005615:0.006209:0.005570:0.014518:0.009039:0.005570:0.008994:0.010820:0.011550:0.005182:0.011391:0.005570:0.011322:0.009131:0.006209:0.009106:0.009108:0.006437:0.005570:0.006620:0.011299:0.009039:0.005570:0.009838:0.009405:0.005250:0.005547:0.011573:0.008811:0.006209:0.009108:0.011391:0.005570:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.005570:0.010112:0.015089:0.007670:0.005570:0.005615:0.011756:0.005570:0.008994:0.006209:0.015773:0.015406:0.014929:0.005570:0.010843:0.006209:0.005570:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.005570:0.014586:0.007875:0.008994:0.005273:0.006209:0.009039:0.007670:0.005570:0.005638:0.005296:0.011413:0.005545:0.011119:0.004497:0.004109
which is known to contain cfDNA and ctDNA  was available for Ova2 at time of dis-:@0.117647:0.210001:0.852941:0.210001:0.852941:0.189628:0.117647:0.189628:0.014792:0.011459:0.005547:0.008765:0.011459:0.005090:0.005615:0.007670:0.005090:0.010706:0.011596:0.010866:0.014723:0.011756:0.005090:0.006209:0.011048:0.005090:0.008994:0.010843:0.011391:0.006551:0.009085:0.005615:0.011756:0.005090:0.008994:0.006209:0.015773:0.015408:0.014929:0.005090:0.009087:0.011596:0.011391:0.005090:0.009108:0.006437:0.015773:0.015408:0.014929:0.018260:0.005090:0.014723:0.009291:0.007670:0.005090:0.008925:0.009838:0.009085:0.005752:0.005433:0.009108:0.010911:0.005182:0.009039:0.005090:0.006026:0.010843:0.007807:0.005090:0.016892:0.009838:0.009291:0.010432:0.005090:0.008813:0.006437:0.005090:0.006437:0.005615:0.017485:0.009039:0.005090:0.010843:0.006209:0.005090:0.011391:0.005615:0.007687:0.007533
361:@0.514782:0.202385:0.533027:0.202385:0.533027:0.190508:0.514782:0.190508:0.006082:0.006082:0.006082
ease recurrence. We extracted cfDNA from the ascites and tested the 16 validated so-:@0.117647:0.230580:0.852941:0.230580:0.852941:0.210207:0.117647:0.210207:0.009291:0.009291:0.007875:0.009039:0.006186:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011596:0.008994:0.008743:0.004497:0.006186:0.018649:0.009039:0.006186:0.009108:0.010089:0.006437:0.007898:0.009291:0.009108:0.006209:0.009108:0.011391:0.006186:0.008994:0.006209:0.015773:0.015408:0.014929:0.006186:0.006414:0.007442:0.010843:0.017645:0.006186:0.006620:0.011299:0.009039:0.006186:0.009291:0.007875:0.008994:0.005273:0.006209:0.009039:0.007670:0.006186:0.009087:0.011596:0.011391:0.006186:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.006186:0.006620:0.011299:0.009039:0.006186:0.010432:0.010432:0.006186:0.009838:0.009402:0.005250:0.005547:0.011573:0.008811:0.006209:0.009108:0.011391:0.006186:0.007875:0.011000:0.007533
matic SVs out of the Top20 by PCR. 100% of somatic SVs could be detected within the :@0.117647:0.251159:0.857171:0.251159:0.857171:0.230786:0.117647:0.230786:0.017577:0.008811:0.006437:0.005547:0.008994:0.004931:0.010112:0.015089:0.007670:0.004931:0.010818:0.011071:0.006437:0.004931:0.010843:0.006209:0.004931:0.006620:0.011299:0.009039:0.004931:0.010866:0.010820:0.011276:0.010432:0.010432:0.004919:0.010843:0.009724:0.004931:0.012167:0.014678:0.013694:0.004497:0.004931:0.010432:0.010432:0.010432:0.015043:0.004931:0.010843:0.006209:0.004919:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004931:0.010112:0.015089:0.007670:0.004931:0.008994:0.010820:0.011550:0.005179:0.011391:0.004931:0.011254:0.009039:0.004931:0.011322:0.009131:0.006209:0.009108:0.009108:0.006209:0.009106:0.011391:0.004931:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004919:0.006620:0.011302:0.009039:0.004109
cfDNA from ascites (:@0.117647:0.271738:0.297109:0.271738:0.297109:0.251365:0.117647:0.251365:0.008994:0.006209:0.015773:0.015408:0.014929:0.004839:0.006414:0.007439:0.010845:0.017645:0.004839:0.009291:0.007873:0.008994:0.005273:0.006209:0.009039:0.007670:0.004839:0.006939
Suppl. Figure 7:@0.297102:0.271738:0.432602:0.271738:0.432602:0.250605:0.297102:0.250605:0.010455:0.011893:0.011733:0.011779:0.005661:0.005433:0.004725:0.011598:0.006209:0.010749:0.011893:0.008263:0.009473:0.004725:0.010911
), and not in the germline or water controls. Next, :@0.432609:0.271738:0.857075:0.271738:0.857075:0.251365:0.432609:0.251365:0.006939:0.004497:0.004839:0.009085:0.011596:0.011391:0.004839:0.011596:0.010820:0.006437:0.004839:0.005615:0.011756:0.004839:0.006620:0.011299:0.009039:0.004839:0.009656:0.009039:0.007807:0.017759:0.005250:0.005615:0.011596:0.009039:0.004839:0.010843:0.007807:0.004839:0.014723:0.008811:0.006209:0.009039:0.007807:0.004839:0.008994:0.010843:0.011391:0.006437:0.007442:0.010936:0.005250:0.007670:0.004497:0.004839:0.015522:0.009108:0.010089:0.006437:0.004497:0.004109
we tested whether validated SVs could be detected in cfDNA from blood. Therefore, :@0.117647:0.292316:0.857075:0.292316:0.857075:0.271943:0.117647:0.271943:0.014518:0.009039:0.006780:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.006780:0.014792:0.011299:0.009131:0.006620:0.011299:0.009039:0.007807:0.006780:0.009838:0.009405:0.005250:0.005547:0.011573:0.008811:0.006209:0.009108:0.011391:0.006780:0.010112:0.015089:0.007670:0.006780:0.008994:0.010820:0.011550:0.005182:0.011391:0.006780:0.011254:0.009039:0.006780:0.011322:0.009131:0.006209:0.009108:0.009108:0.006209:0.009108:0.011391:0.006780:0.005615:0.011756:0.006780:0.008994:0.006209:0.015773:0.015408:0.014929:0.006780:0.006414:0.007442:0.010843:0.017645:0.006780:0.010911:0.005182:0.011276:0.011276:0.011117:0.004497:0.006780:0.011470:0.011311:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.008743:0.004497:0.004109
we selected two patient-specific SVs for four prostate cancer patients (Pros1, 4, 5 and 6) :@0.117647:0.312895:0.857050:0.312895:0.857050:0.292522:0.117647:0.292522:0.014518:0.009039:0.004645:0.007875:0.008948:0.005182:0.009108:0.009108:0.006209:0.009108:0.011391:0.004645:0.006437:0.014518:0.011048:0.004645:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.004645:0.010112:0.015089:0.007670:0.004645:0.006026:0.010843:0.007807:0.004645:0.006026:0.010820:0.011413:0.007807:0.004645:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.004645:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004645:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004645:0.006939:0.011916:0.007442:0.010957:0.007670:0.010432:0.004497:0.004645:0.010432:0.004497:0.004645:0.010432:0.004645:0.009085:0.011596:0.011391:0.004645:0.010432:0.006939:0.004109
based on a high signal to noise ratio observed in qPCR assays for SV breakpoints (:@0.117647:0.333474:0.794753:0.333474:0.794753:0.313101:0.117647:0.313101:0.011117:0.009291:0.007875:0.009108:0.011391:0.003470:0.010843:0.011756:0.003470:0.009291:0.003470:0.011459:0.005615:0.009930:0.011459:0.003470:0.007601:0.005615:0.009861:0.011687:0.009405:0.005250:0.003470:0.006209:0.011048:0.003470:0.011596:0.010843:0.005615:0.007875:0.009039:0.003470:0.007898:0.008811:0.006437:0.005547:0.011048:0.003470:0.010957:0.010934:0.007875:0.009039:0.008398:0.009635:0.009106:0.011391:0.003470:0.005615:0.011756:0.003470:0.011025:0.012167:0.014678:0.013376:0.003470:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.003470:0.006026:0.010843:0.007807:0.003470:0.010112:0.015089:0.003470:0.010820:0.007442:0.009288:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.007670:0.003470:0.006939
Figure :@0.794756:0.333474:0.856959:0.333474:0.856959:0.312341:0.794756:0.312341:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004018
4A:@0.117647:0.354052:0.143647:0.354052:0.143647:0.332919:0.117647:0.332919:0.010911:0.015089
 and Methods). :@0.143647:0.354052:0.275837:0.354052:0.275837:0.333679:0.143647:0.333679:0.004109:0.009085:0.011596:0.011391:0.004109:0.018969:0.009131:0.006620:0.011299:0.011276:0.011391:0.007670:0.006939:0.004497:0.004109
To enable sensitive and quantitative detection, we designed digital PCR (dPCR) assays :@0.117647:0.374631:0.856979:0.374631:0.856979:0.354258:0.117647:0.354258:0.010866:0.011048:0.005501:0.009039:0.011687:0.009108:0.010911:0.005182:0.009039:0.005501:0.007873:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.005501:0.009085:0.011596:0.011391:0.005501:0.010706:0.011596:0.009085:0.011391:0.006437:0.005273:0.006551:0.008811:0.006437:0.005547:0.009633:0.009039:0.005501:0.011322:0.009131:0.006209:0.009108:0.009106:0.006437:0.005549:0.010840:0.011756:0.004497:0.005501:0.014518:0.009039:0.005501:0.011322:0.009039:0.007601:0.005615:0.009861:0.011596:0.009108:0.011391:0.005501:0.011391:0.005615:0.009861:0.005273:0.006551:0.009405:0.005250:0.005501:0.012167:0.014678:0.013376:0.005501:0.006939:0.011391:0.012167:0.014678:0.013376:0.006939:0.005501:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.004109
for the eight selected SVs (:@0.117647:0.395210:0.339818:0.395210:0.339818:0.374837:0.117647:0.374837:0.006026:0.010843:0.007807:0.004337:0.006620:0.011299:0.009039:0.004337:0.009039:0.005615:0.009930:0.011094:0.006437:0.004337:0.007875:0.008948:0.005182:0.009108:0.009108:0.006207:0.009108:0.011391:0.004337:0.010112:0.015089:0.007670:0.004337:0.006939
Figure 4B:@0.339840:0.395210:0.426947:0.395210:0.426947:0.374077:0.339840:0.374077:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004246:0.010911:0.013765
). For each SV, we aimed to design a probe for both :@0.426946:0.395210:0.857000:0.395210:0.857000:0.374837:0.426946:0.374837:0.006939:0.004497:0.004337:0.010683:0.010843:0.007807:0.004337:0.009291:0.009291:0.008765:0.011459:0.004337:0.010112:0.011482:0.004497:0.004337:0.014518:0.009039:0.004337:0.009085:0.005615:0.017485:0.009108:0.011391:0.004337:0.006209:0.011048:0.004337:0.011322:0.009039:0.007601:0.005615:0.009861:0.011756:0.004337:0.009291:0.004337:0.011071:0.007442:0.010957:0.011251:0.009039:0.004337:0.006026:0.010843:0.007807:0.004337:0.011254:0.010820:0.006620:0.011459:0.004109
wild-type alleles (up- and downstream) and for the mutant allele (across the breakpoint :@0.117647:0.415788:0.857050:0.415788:0.857050:0.395416:0.117647:0.395416:0.014723:0.005752:0.005182:0.011391:0.007533:0.006437:0.009724:0.011502:0.009039:0.004497:0.009405:0.005387:0.005182:0.008948:0.005182:0.009039:0.007670:0.004497:0.006939:0.011071:0.011276:0.007533:0.004497:0.009085:0.011596:0.011391:0.004497:0.011322:0.010866:0.014723:0.011619:0.007510:0.006437:0.007442:0.009291:0.009085:0.017645:0.006939:0.004497:0.009085:0.011596:0.011391:0.004497:0.006026:0.010843:0.007807:0.004497:0.006620:0.011299:0.009039:0.004497:0.017280:0.011071:0.006551:0.009085:0.011391:0.006437:0.004497:0.009405:0.005387:0.005182:0.008948:0.005182:0.009039:0.004497:0.006939:0.009291:0.008994:0.007442:0.010957:0.007533:0.007670:0.004497:0.006620:0.011299:0.009039:0.004497:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.004109
junction). For five SVs we could design an assay that quantified both the upstream and :@0.117647:0.436367:0.857007:0.436367:0.857007:0.415994:0.117647:0.415994:0.004953:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011756:0.006939:0.004497:0.005022:0.010683:0.010843:0.007807:0.005022:0.005684:0.005615:0.009633:0.009039:0.005022:0.010112:0.015089:0.007670:0.005022:0.014518:0.009039:0.005022:0.008994:0.010820:0.011550:0.005182:0.011391:0.005022:0.011324:0.009039:0.007601:0.005615:0.009861:0.011756:0.005022:0.009085:0.011756:0.005022:0.009291:0.007533:0.007944:0.008925:0.009724:0.005022:0.006620:0.011391:0.008811:0.006437:0.005022:0.010706:0.011596:0.009085:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.011391:0.005022:0.011251:0.010820:0.006620:0.011459:0.005022:0.006620:0.011299:0.009039:0.005022:0.011071:0.011185:0.007510:0.006437:0.007442:0.009291:0.009085:0.017645:0.005022:0.009085:0.011596:0.011391:0.004109
downstream wild-type allele. For the three other SVs, primers/probes for only one of :@0.117647:0.456946:0.857048:0.456946:0.857048:0.436573:0.117647:0.436573:0.011322:0.010866:0.014723:0.011619:0.007510:0.006437:0.007442:0.009291:0.009085:0.017645:0.006346:0.014723:0.005752:0.005182:0.011391:0.007533:0.006437:0.009724:0.011502:0.009039:0.006346:0.009405:0.005387:0.005182:0.008948:0.005182:0.008743:0.004497:0.006346:0.010683:0.010843:0.007807:0.006346:0.006620:0.011299:0.009039:0.006346:0.006620:0.011459:0.007442:0.009108:0.009039:0.006346:0.010820:0.006620:0.011299:0.009039:0.007807:0.006346:0.010112:0.015089:0.007670:0.004497:0.006346:0.011071:0.007807:0.005615:0.017483:0.009039:0.007624:0.007670:0.007099:0.011071:0.007442:0.010957:0.011254:0.009039:0.007670:0.006346:0.006026:0.010843:0.007807:0.006346:0.010843:0.011870:0.005182:0.009724:0.006346:0.010843:0.011596:0.009039:0.006346:0.010843:0.006209:0.004109
the wild-type alleles were designed, as appropriate primer design for the other allele was :@0.117647:0.477525:0.857048:0.477525:0.857048:0.457152:0.117647:0.457152:0.006620:0.011299:0.009039:0.004269:0.014723:0.005752:0.005182:0.011391:0.007533:0.006437:0.009724:0.011502:0.009039:0.004269:0.009405:0.005387:0.005182:0.008948:0.005182:0.009039:0.007670:0.004269:0.014518:0.009039:0.007442:0.009039:0.004269:0.011322:0.009039:0.007601:0.005615:0.009861:0.011596:0.009108:0.011117:0.004497:0.004269:0.009291:0.007670:0.004269:0.008811:0.011048:0.011071:0.007442:0.010820:0.011071:0.007807:0.005798:0.008811:0.006209:0.009039:0.004269:0.011071:0.007807:0.005615:0.017485:0.009039:0.007807:0.004269:0.011322:0.009039:0.007601:0.005615:0.009861:0.011756:0.004269:0.006024:0.010845:0.007807:0.004269:0.006620:0.011299:0.009039:0.004269:0.010820:0.006617:0.011302:0.009039:0.007807:0.004269:0.009402:0.005387:0.005182:0.008948:0.005182:0.009039:0.004269:0.014723:0.009291:0.007670:0.004109
hindered by repetitive sequences at the target site. As the amount of cfDNA within one :@0.117647:0.498103:0.857098:0.498103:0.857098:0.477730:0.117647:0.477730:0.011459:0.005615:0.011596:0.011322:0.009039:0.007442:0.009108:0.011391:0.004908:0.010843:0.009724:0.004908:0.007442:0.009131:0.011505:0.009128:0.006437:0.005273:0.006437:0.005547:0.009633:0.009039:0.004908:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009039:0.007670:0.004908:0.008811:0.006437:0.004908:0.006620:0.011299:0.009039:0.004908:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.004908:0.007601:0.005273:0.006209:0.008743:0.004497:0.004908:0.014586:0.007670:0.004908:0.006620:0.011299:0.009039:0.004908:0.009087:0.017485:0.010820:0.011413:0.011391:0.006437:0.004908:0.010843:0.006209:0.004908:0.008994:0.006209:0.015773:0.015408:0.014929:0.004908:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004908:0.010843:0.011596:0.009039:0.004109
liquid biopsy is limited, we used a conditional breakpoint detection approach: (i) if dPCR :@0.117647:0.518682:0.857027:0.518682:0.857027:0.498309:0.117647:0.498309:0.005250:0.005547:0.010706:0.011413:0.005547:0.011391:0.003287:0.010820:0.005547:0.010820:0.011185:0.007759:0.009724:0.003287:0.005615:0.007670:0.003287:0.005250:0.005615:0.017645:0.005273:0.006209:0.009108:0.011117:0.004497:0.003287:0.014518:0.009039:0.003287:0.011413:0.007875:0.009108:0.011391:0.003287:0.009291:0.003287:0.008994:0.010843:0.011596:0.011391:0.005273:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.003287:0.010822:0.007442:0.009288:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.003287:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.003287:0.008811:0.011048:0.011071:0.007442:0.011139:0.009291:0.008765:0.011459:0.004497:0.003287:0.006939:0.005615:0.006939:0.003287:0.005615:0.006209:0.003287:0.011391:0.012167:0.014678:0.013376:0.004109
on pre-amplified cfDNA (input pre-amplification: 0.2-1 ng cfDNA) confirmed the pres-:@0.117647:0.539261:0.852941:0.539261:0.852941:0.518888:0.117647:0.518888:0.010843:0.011756:0.004040:0.011071:0.007442:0.009039:0.007533:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009108:0.011391:0.004040:0.008994:0.006209:0.015773:0.015408:0.014929:0.004040:0.006939:0.005615:0.011391:0.011048:0.011071:0.006437:0.004040:0.011071:0.007442:0.009039:0.007533:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.004040:0.010432:0.004497:0.010432:0.007533:0.010432:0.004040:0.011459:0.009861:0.004040:0.008994:0.006209:0.015771:0.015408:0.014929:0.006939:0.004040:0.008994:0.010845:0.011756:0.005684:0.005684:0.007807:0.017485:0.009108:0.011391:0.004040:0.006620:0.011299:0.009039:0.004040:0.011071:0.007442:0.009039:0.007736:0.007533
ence of the SV within cfDNA, (ii) then subsequent dPCR on non-preamplified cfDNA :@0.117647:0.559839:0.857005:0.559839:0.857005:0.539466:0.117647:0.539466:0.009039:0.011596:0.008994:0.009039:0.005113:0.010843:0.006209:0.005113:0.006620:0.011299:0.009039:0.005113:0.010112:0.015089:0.005113:0.014723:0.005271:0.006620:0.011459:0.005615:0.011756:0.005113:0.008994:0.006209:0.015773:0.015408:0.014929:0.004497:0.005113:0.006939:0.005615:0.005615:0.006939:0.005113:0.006617:0.011302:0.009039:0.011756:0.005113:0.007510:0.011345:0.010934:0.007875:0.009108:0.010706:0.011345:0.009039:0.011391:0.006437:0.005113:0.011391:0.012167:0.014678:0.013376:0.005113:0.010843:0.011756:0.005113:0.011596:0.010843:0.011756:0.007533:0.011071:0.007442:0.009291:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009108:0.011391:0.005113:0.008994:0.006209:0.015773:0.015408:0.014929:0.004109
(stock cfDNA) (input dPCR: 5 ng cfDNA) was performed. The latter enabled calcula-:@0.117647:0.580418:0.852941:0.580418:0.852941:0.560045:0.117647:0.560045:0.006939:0.007510:0.006209:0.011276:0.008765:0.010523:0.006003:0.008994:0.006209:0.015771:0.015408:0.014929:0.006939:0.006003:0.006939:0.005615:0.011391:0.011048:0.011071:0.006437:0.006003:0.011391:0.012167:0.014678:0.013376:0.004497:0.006003:0.010432:0.006003:0.011459:0.009861:0.006003:0.008994:0.006209:0.015773:0.015408:0.014929:0.006939:0.006003:0.014723:0.009291:0.007670:0.006003:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011117:0.004497:0.006003:0.011470:0.011311:0.009039:0.006003:0.005433:0.008811:0.006163:0.006209:0.009039:0.007807:0.006003:0.009039:0.011687:0.009108:0.010911:0.005182:0.009108:0.011391:0.006003:0.009108:0.009405:0.005182:0.009108:0.011550:0.005433:0.009222:0.007533
tion of both the variant allele frequency (VAF) and the number of mutant molecules :@0.117647:0.600997:0.857096:0.600997:0.857096:0.580624:0.117647:0.580624:0.006437:0.005547:0.010843:0.011756:0.006551:0.010843:0.006209:0.006551:0.011254:0.010820:0.006620:0.011459:0.006551:0.006620:0.011299:0.009039:0.006551:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.006551:0.009405:0.005387:0.005182:0.008948:0.005182:0.009039:0.006551:0.006412:0.007442:0.009108:0.010706:0.011345:0.009039:0.011596:0.009382:0.009724:0.006551:0.006825:0.012578:0.014929:0.011368:0.006939:0.006551:0.009085:0.011596:0.011391:0.006551:0.006620:0.011299:0.009039:0.006551:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.006551:0.010843:0.006209:0.006551:0.017280:0.011071:0.006551:0.009085:0.011391:0.006437:0.006551:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005182:0.009039:0.007670:0.004109
per milliliter plasma (MM/mL plasma). First, we selected two timepoints per patient, :@0.117647:0.621575:0.857002:0.621575:0.857002:0.601203:0.117647:0.601203:0.011505:0.009039:0.007807:0.006300:0.017645:0.005752:0.005387:0.005250:0.005750:0.005250:0.005273:0.006209:0.009039:0.007807:0.006300:0.011162:0.005433:0.009291:0.007601:0.017577:0.009291:0.006300:0.006939:0.019608:0.019608:0.007099:0.017645:0.011619:0.006300:0.011162:0.005433:0.009291:0.007601:0.017577:0.009291:0.006939:0.004497:0.006300:0.011388:0.005615:0.007624:0.007512:0.006437:0.004497:0.006300:0.014518:0.009039:0.006300:0.007875:0.008948:0.005182:0.009106:0.009108:0.006209:0.009108:0.011391:0.006300:0.006437:0.014518:0.011048:0.006300:0.006437:0.005615:0.017485:0.009131:0.011505:0.010843:0.005615:0.011391:0.006437:0.007670:0.006300:0.011505:0.009039:0.007807:0.006300:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004497:0.004109
one at baseline and one at progression of disease and confirmed the presence of all eight :@0.117647:0.642154:0.857048:0.642154:0.857048:0.621781:0.117647:0.621781:0.010843:0.011596:0.009039:0.004223:0.008811:0.006437:0.004223:0.011117:0.009291:0.007875:0.008948:0.005250:0.005615:0.011596:0.009039:0.004223:0.009085:0.011596:0.011391:0.004223:0.010843:0.011596:0.009039:0.004223:0.008811:0.006437:0.004223:0.011071:0.007442:0.011048:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.004223:0.010843:0.006209:0.004223:0.011391:0.005615:0.007873:0.009291:0.009291:0.007875:0.009039:0.004223:0.009085:0.011596:0.011391:0.004223:0.008994:0.010843:0.011756:0.005684:0.005684:0.007807:0.017485:0.009108:0.011391:0.004223:0.006620:0.011299:0.009039:0.004223:0.011071:0.007442:0.009039:0.007875:0.009039:0.011596:0.008994:0.009039:0.004223:0.010843:0.006209:0.004223:0.009405:0.005385:0.005250:0.004223:0.009039:0.005615:0.009930:0.011094:0.006437:0.004109
SVs with dPCR on pre-amplified cfDNA (:@0.117647:0.662733:0.485636:0.662733:0.485636:0.642360:0.117647:0.642360:0.010112:0.015089:0.007670:0.006551:0.014723:0.005271:0.006620:0.011459:0.006551:0.011391:0.012167:0.014678:0.013376:0.006551:0.010843:0.011756:0.006551:0.011071:0.007442:0.009039:0.007533:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009108:0.011391:0.006551:0.008994:0.006209:0.015773:0.015408:0.014929:0.006551:0.006939
Suppl. Figure 8:@0.485656:0.662733:0.624532:0.662733:0.624532:0.641600:0.485656:0.641600:0.010455:0.011893:0.011733:0.011779:0.005661:0.005433:0.006414:0.011596:0.006209:0.010749:0.011893:0.008263:0.009473:0.006414:0.010911
). Thereafter, dPCR on the :@0.624523:0.662733:0.857036:0.662733:0.857036:0.642360:0.624523:0.642360:0.006939:0.004497:0.006551:0.011470:0.011311:0.009039:0.007442:0.009291:0.009085:0.006197:0.005971:0.009039:0.006252:0.004497:0.006551:0.011391:0.012167:0.014678:0.013376:0.006551:0.010843:0.011756:0.006551:0.006620:0.011299:0.009039:0.004109
stock cfDNA successfully detected all SVs in the four patients, both in baseline and pro-:@0.117647:0.683312:0.852941:0.683312:0.852941:0.662939:0.117647:0.662939:0.007510:0.006209:0.011276:0.008765:0.010523:0.004212:0.008994:0.006209:0.015773:0.015408:0.014929:0.004212:0.007510:0.011345:0.008994:0.008994:0.009039:0.007533:0.007601:0.006369:0.011550:0.005387:0.005182:0.009724:0.004212:0.011322:0.009131:0.006209:0.009108:0.009106:0.006211:0.009106:0.011391:0.004212:0.009405:0.005387:0.005250:0.004212:0.010112:0.015089:0.007670:0.004212:0.005615:0.011756:0.004212:0.006620:0.011299:0.009039:0.004212:0.006026:0.010820:0.011413:0.007807:0.004212:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.004212:0.011254:0.010820:0.006617:0.011459:0.004212:0.005615:0.011756:0.004209:0.011117:0.009291:0.007875:0.008948:0.005250:0.005615:0.011596:0.009039:0.004212:0.009085:0.011596:0.011391:0.004212:0.011071:0.007442:0.011053:0.007533
gression samples (:@0.117647:0.703890:0.274079:0.703890:0.274079:0.683517:0.117647:0.683517:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.006255:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.006255:0.006939
Figure 4C and 4D:@0.274084:0.703890:0.437432:0.703890:0.437432:0.682757:0.274084:0.682757:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.006118:0.010911:0.014769:0.006118:0.009656:0.012167:0.011870:0.006118:0.010911:0.016527
). Despite the fact that the VAF in pre-amplified :@0.437432:0.703890:0.857034:0.703890:0.857034:0.683517:0.437432:0.683517:0.006939:0.004497:0.006255:0.016230:0.009039:0.007510:0.011071:0.005273:0.006209:0.009039:0.006255:0.006620:0.011299:0.009039:0.006255:0.006209:0.009291:0.009108:0.006437:0.006255:0.006620:0.011391:0.008811:0.006437:0.006255:0.006620:0.011299:0.009039:0.006255:0.012578:0.014929:0.011276:0.006255:0.005615:0.011756:0.006255:0.011071:0.007442:0.009039:0.007533:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009108:0.011391:0.004109
cfDNA correlates to the VAF in stock cfDNA (r = 0.928), they should be considered two :@0.117647:0.724469:0.857004:0.724469:0.857004:0.704096:0.117647:0.704096:0.008994:0.006209:0.015773:0.015408:0.014929:0.003995:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006209:0.009039:0.007670:0.003995:0.006209:0.011048:0.003995:0.006617:0.011302:0.009039:0.003995:0.012578:0.014929:0.011276:0.003995:0.005615:0.011756:0.003995:0.007510:0.006209:0.011276:0.008765:0.010523:0.003995:0.008994:0.006209:0.015773:0.015408:0.014929:0.003995:0.006939:0.007807:0.006685:0.011779:0.003995:0.010432:0.004497:0.010432:0.010432:0.010432:0.006939:0.004497:0.003995:0.006620:0.011299:0.009336:0.009724:0.003995:0.007556:0.011299:0.010820:0.011550:0.005182:0.011391:0.003995:0.011254:0.009039:0.003995:0.008994:0.010843:0.011619:0.007601:0.005547:0.011322:0.009039:0.007442:0.009108:0.011391:0.003995:0.006437:0.014518:0.011048:0.004109
s :@0.512705:0.727621:0.519572:0.727621:0.519572:0.715744:0.512705:0.715744:0.004472:0.002395
separate outcome measurements (regression coefficient = 0.72 ≠ 1) (:@0.117647:0.745048:0.691328:0.745048:0.691328:0.724675:0.117647:0.724675:0.007875:0.009131:0.011368:0.009085:0.007898:0.008811:0.006209:0.009039:0.004611:0.010820:0.011071:0.006209:0.008994:0.010843:0.017485:0.009039:0.004611:0.017485:0.009291:0.009291:0.007510:0.011413:0.007442:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.004611:0.006939:0.007442:0.009039:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.004611:0.008994:0.011276:0.009039:0.005692:0.005692:0.005621:0.008994:0.005547:0.009039:0.011391:0.006437:0.004611:0.011779:0.004611:0.010432:0.004497:0.010432:0.010432:0.004611:0.012167:0.004611:0.010432:0.006939:0.004611:0.006939
Suppl. Figure 9A:@0.691347:0.745048:0.841522:0.745048:0.841522:0.723915:0.691347:0.723915:0.010455:0.011893:0.011733:0.011779:0.005661:0.005433:0.004520:0.011596:0.006209:0.010751:0.011893:0.008261:0.009473:0.004520:0.010911:0.015089
). :@0.841505:0.745048:0.857050:0.745048:0.857050:0.724675:0.841505:0.724675:0.006939:0.004497:0.004109
Moreover, VAF based on the wild-type upstream allele was highly similar to VAF based :@0.117647:0.765626:0.856998:0.765626:0.856998:0.745253:0.117647:0.745253:0.018969:0.010843:0.007442:0.009108:0.010866:0.009633:0.009039:0.006255:0.004497:0.004497:0.012578:0.014929:0.011276:0.004497:0.011117:0.009291:0.007875:0.009108:0.011391:0.004497:0.010843:0.011756:0.004497:0.006620:0.011299:0.009039:0.004497:0.014723:0.005752:0.005182:0.011391:0.007533:0.006437:0.009724:0.011502:0.009039:0.004497:0.011071:0.011185:0.007510:0.006437:0.007442:0.009291:0.009085:0.017645:0.004497:0.009402:0.005387:0.005182:0.008948:0.005182:0.009039:0.004497:0.014723:0.009291:0.007670:0.004497:0.011459:0.005615:0.009927:0.011573:0.005182:0.009724:0.004497:0.007601:0.005615:0.017645:0.005752:0.005433:0.009085:0.007807:0.004497:0.006209:0.011048:0.004497:0.012578:0.014929:0.011276:0.004497:0.011114:0.009291:0.007875:0.009108:0.011391:0.004109
on the wild-type downstream allele in stock cfDNA (r = 0.996, regression coefficient = :@0.117647:0.786205:0.857031:0.786205:0.857031:0.765832:0.117647:0.765832:0.010843:0.011756:0.005182:0.006620:0.011299:0.009039:0.005182:0.014723:0.005750:0.005184:0.011391:0.007533:0.006437:0.009724:0.011502:0.009039:0.005182:0.011322:0.010866:0.014723:0.011619:0.007510:0.006437:0.007442:0.009291:0.009085:0.017645:0.005182:0.009402:0.005387:0.005184:0.008948:0.005182:0.009039:0.005182:0.005615:0.011756:0.005182:0.007510:0.006209:0.011276:0.008765:0.010523:0.005182:0.008994:0.006209:0.015773:0.015408:0.014929:0.005182:0.006939:0.007807:0.007354:0.011779:0.005182:0.010432:0.004497:0.010432:0.010432:0.010432:0.004497:0.005182:0.007442:0.009039:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.005182:0.008994:0.011276:0.009039:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006437:0.005182:0.011779:0.004109
s :@0.576596:0.789358:0.583463:0.789358:0.583463:0.777480:0.576596:0.777480:0.004472:0.002395
1.05) (:@0.117647:0.806784:0.171641:0.806784:0.171641:0.786411:0.117647:0.786411:0.010432:0.004497:0.010432:0.010432:0.006939:0.004323:0.006939
Suppl. Figure 9B:@0.171641:0.806784:0.319901:0.806784:0.319901:0.785651:0.171641:0.785651:0.010455:0.011893:0.011733:0.011779:0.005661:0.005433:0.004223:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004223:0.010911:0.013765
), suggesting no significant imbalances between the two sides of :@0.319911:0.806784:0.857051:0.806784:0.857051:0.786411:0.319911:0.786411:0.006939:0.004497:0.004326:0.007510:0.011413:0.009973:0.009658:0.009039:0.007510:0.006437:0.005615:0.011457:0.009861:0.004326:0.011596:0.011048:0.004326:0.007601:0.005615:0.009861:0.011756:0.005615:0.005684:0.005615:0.009106:0.009087:0.011391:0.006437:0.004323:0.005615:0.017394:0.011117:0.009405:0.005433:0.009085:0.011596:0.008994:0.009039:0.007670:0.004326:0.011254:0.009128:0.006437:0.014520:0.009106:0.009039:0.011756:0.004326:0.006620:0.011299:0.009039:0.004326:0.006437:0.014518:0.011048:0.004323:0.007601:0.005547:0.011322:0.009039:0.007670:0.004326:0.010843:0.006209:0.004109
the breakpoint. :@0.117647:0.827362:0.250339:0.827362:0.250339:0.806990:0.117647:0.806990:0.006620:0.011299:0.009039:0.004109:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.004497:0.004109